Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats

Drug Metabolism and Disposition

Volumn 41, Issue 8, 2013, Pages 1592-1597

  Kunimatsu, Sachiko ^a   Mizuno, Tomoyuki ^a   Fukudo, Masahide ^a   Katsura, Toshiya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PANTOPRAZOLE; SUNITINIB; VALSPODAR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; INHIBITION KINETICS; KIDNEY PARENCHYMA; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TANDEM MASS SPECTROMETRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BRAIN; INDOLES; MALE; P-GLYCOPROTEIN; PYRROLES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84880667458     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050286     Document Type: Article

References (33)

1. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, and Lou Y, et al. (2010) Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 99: 1046-1062.
2. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147-155.
3. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, and Klamerus KJ (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17: 353-358.
4. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and Pglycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65: 2577-2582.
5. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, and Slamon D (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61:515-524.
6. Chow LQ and Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896.
7. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, and Morgan JA, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338.
8. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, and Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551-603.
9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, and Massimini G, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35.
10. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, and Egorin MJ (2000) Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18:1124-1134.
11. Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, and Wu J, et al. (2009) Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27:4599-4604.
12. Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li HZ, Lin HJ, Zhao Y, Wei M, and Cheng K, et al. (2011) Interaction of green tea polyphenol epigallocatechin-3- gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl) 89:595-602.
13. Glavinas H, Krajcsi P, Cserepes J, and Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27-42.
14. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, and Rha SY (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41:67-72.
15. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, and Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATPbinding cassette transporters. Clin Cancer Res 15:6062-6069.
16. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
17. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 9:319-326.
18. Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, and Katsura T (2012) Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet 27:631-639.
19. Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, and Inui K (2010) ABCG2 421C.A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382-1383.
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, and Bjarnason GA, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590.
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, and Kim ST, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
22. Muenster U, Grieshop B, Ickenroth K, and Gnoth MJ (2008) Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25: 2320-2326.
23. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, and Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
24. Poller B, Wagenaar E, Tang SC, and Schinkel AH (2011) Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 8:571-582.
25. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl] aminomethyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
26. Shukla S, Robey RW, Bates SE, and Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a smallmolecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365.
27. Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, and Kang P (2012) Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40:539-555.
28. Tai HL (2000) Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther 2:459-467.
29. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, and Schinkel AH (2012) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233.
30. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, and Takahashi M, et al. (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194-202.
31. van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den Hartigh J, König-Quartel JM, Guchelaar HJ, and Gelderblom H (2011) Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 67:695-703.
32. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, and Inui K (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128.
33. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, and Hong B, et al. (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40: 980-985.